Skip to Content

Weekly Wrap: How the Pandemic Has Changed the Math on Emergency Funds and College Savings

We recap the week on Morningstar.com and note the most popular stocks, funds, and exchange-traded funds.

Editor's note: Read the latest on how the coronavirus is rattling the markets and what investors can do to navigate it.

Editor's Picks Why Become an ESG Investor? The question is not rhetorical. Stakeholder Votes Divided on Social Justice Proxy voting reveals disagreement between the influential majority and smaller shareholders on diversity, equity, and inclusion issues. 529 College Savings Plans During the Pandemic Here's how they've been performing and what college savers should be thinking about today. How Can Advisors Help Clients Through Market Anxiety? Our research explored three tactics for dissuading client fears about increased volatility. The New Math on Emergency Funds Don't eat that first potato chip.

Portfolio Planning and Personal Finance With Christine Benz Ramit Sethi: 'Question What You've Been Told About Buying a House' The author of the best-selling book, "I Will Teach You to Be Rich," on how homeownership fits into a financial plan.

Mutual Funds and Exchange-Traded Funds What Top Fund Managers Are Buying and Selling Across the board, Morningstar Medalists got defensive in the third quarter.

Stocks Electricity Demand's COVID Comeback Utilities should benefit as the U.S. economy electrifies. What Is Gold Worth? And do any other assets currently compare? Our Ultimate Stock-Pickers' Top 10 High-Conviction Purchases Several funds see value in basic materials and industrials. There's Still Gas in Ford's Tank The legendary pony takes on Tesla and aims for pole position on profitability.

Stock Analyst Updates Astra and Oxford Report Strong COVID-19 Vaccine Astra's vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines. Regeneron Authorized to Use Antibody Cocktail We're maintaining our $500 fair value estimate for the narrow-moat drug manufacturer.

Advisor Insights Building a Niche Advisory Firm From the Ground Up Knowing your customer is critical.

Most Requested Stock Quotes Apple Tesla Pfizer Intel Amazon.com

Most Requested Fund Quotes Vanguard 500 Index Vanguard Dividend Growth T. Rowe Price Blue Chip Growth Fidelity 500 IndexFidelity Contrafund

Most Requested ETF Quotes ARK Innovation ETF Invesco QQQ Trust SPDR S&P 500 ETF Vanguard Total Stock Market ETF Vanguard S&P 500 ETF

More in Portfolios

About the Author

Carole Hodorowicz

Audience Engagement Editor
More from Author

Carole Hodorowicz is an audience engagement editor for Morningstar.com. Focusing on the individual investor audience, she manages content, creates explainer videos, and writes articles about different topics in finance for beginners.

Hodorowicz joined Morningstar in 2015 as a customer support representative for Morningstar Office before moving into an editorial role.

Hodorowicz holds a bachelor’s degree in journalism from Eastern Illinois University.

Sponsor Center